ストックスクリーナーアプリを入手
67.79
2.11%
1.40
前日終値:
$66.39
開ける：
$66.3
24時間の取引高:
1.16M
Relative Volume:
0.51
時価総額：
$9.21B
収益：
$181.74M
当期純損益:
$-143.97M
株価収益率:
-48.77
EPS:
-1.39
ネットキャッシュフロー:
$9.60M
1週間 パフォーマンス:
-3.38%
1か月 パフォーマンス:
+16.98%
6か月 パフォーマンス:
+301.12%
1年 パフォーマンス:
+244.99%
1日の値動き範囲:
$65.00
$68.25
1週間の範囲:
$65.00
$69.69
52週間の値動き範囲:
$9.57
$72.36
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
名前
Arrowhead Pharmaceuticals Inc
セクター
電話
626-696-4702
住所
177 E COLORADO BLVD, PASADENA, CA
ARWR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
67.79 | 9.02B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-05 | 開始されました | Goldman | Neutral |
| 2023-12-04 | 開始されました | BofA Securities | Buy |
| 2023-09-19 | 開始されました | Citigroup | Neutral |
| 2023-07-21 | 開始されました | TD Cowen | Outperform |
| 2023-05-12 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-12 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-11 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 再開されました | Goldman | Buy |
| 2021-08-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-11-19 | 開始されました | Citigroup | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-05-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-04-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 開始されました | Goldman | Neutral |
| 2020-01-21 | 開始されました | SVB Leerink | Underperform |
| 2019-12-13 | 開始されました | Oppenheimer | Perform |
| 2019-11-29 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-27 | 繰り返されました | B. Riley FBR | Buy |
| 2019-11-25 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-10-03 | 開始されました | Robert W. Baird | Outperform |
| 2018-09-07 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-08-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Arrowhead Pharmaceuticals Inc (ARWR) 最新ニュース
Bernstein raises Arrowhead Pharma stock price target to $35 on obesity data - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Evolus (EOLS) - The Globe and Mail
Corient Private Wealth LLC Takes Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells $527,100.00 in Stock - MarketBeat
Ferrari Mauro sells $527k in Arrowhead Pharmaceuticals (ARWR) By Investing.com - Investing.com UK
Ferrari Mauro sells $527k in Arrowhead Pharmaceuticals (ARWR) - Investing.com India
Arrowhead Pharmaceuticals Insider Sold Shares Worth $527,100, According to a Recent SEC Filing - marketscreener.com
Arrowhead Pharmaceuticals Executives Conduct Major Stock Transactions - TradingView — Track All Markets
Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data - ts2.tech
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 3.9%Time to Sell? - MarketBeat
Arrowhead rises as FDA approves lead drug for rare disorder - MSN
These 4 Measures Indicate That Arrowhead Pharmaceuticals (NASDAQ:ARWR) Is Using Debt Reasonably Well - 富途牛牛
Trading the Move, Not the Narrative: (ARWR) Edition - Stock Traders Daily
HBK Sorce Advisory LLC Invests $2.82 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Exchange Traded Concepts LLC Sells 15,265 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Texas Permanent School Fund Corp Buys Shares of 19,104 Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Voya Investment Management LLC Has $4.74 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
76,408 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by HBK Sorce Advisory LLC - MarketBeat
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After FDA Breakthrough Status for Plozasiran and Redemplo Launch - Sahm
Arrowhead Pharma director Waddill sells $566k in stock By Investing.com - Investing.com Australia
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells 12,586 Shares of Stock - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Victoria Vakiener Sells 10,040 Shares - MarketBeat
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 10,000 Shares of Stock - MarketBeat
Arrowhead Pharma director Waddill sells $566k in stock - Investing.com
Olukotun of Arrowhead Pharma sells $676k in stock By Investing.com - Investing.com Nigeria
Arrowhead Pharma director Vakiener sells $679k in stock By Investing.com - Investing.com Nigeria
Olukotun of Arrowhead Pharma sells $676k in stock - Investing.com
Arrowhead Pharma CEO Anzalone sells $1.77m in stock By Investing.com - Investing.com UK
Rate Cut: Can Arrowhead Pharmaceuticals Inc. stock attract ESG capital inflowsPortfolio Gains Summary & Risk Controlled Stock Pick Alerts - moha.gov.vn
First Week of February 2026 Options Trading For Arrowhead Pharmaceuticals (ARWR) - Nasdaq
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events - Business Wire
Arrowhead Pharmaceuticals Insider Sold Shares Worth $5,443,462, According to a Recent SEC Filing - marketscreener.com
Arrowhead Pharmaceuticals, Inc. $ARWR Holdings Boosted by Assenagon Asset Management S.A. - MarketBeat
Christopher Richard Anzalone Sells 85,000 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Is Down 6.1% After First CNS RNAi Alzheimer’s Trial Dosing – Has The Bull Case Changed? - Sahm
Will Arrowhead Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Trade Ideas & AI Forecast Swing Trade Picks - DonanımHaber
Behavioral Patterns of ARWR and Institutional Flows - news.stocktradersdaily.com
Trading Action: Can Arrowhead Pharmaceuticals Inc. stock attract ESG capital inflowsGap Down & Detailed Earnings Play Strategies - moha.gov.vn
Can Arrowhead Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Movers & AI Powered Trade Plan Recommendations - Улправда
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given New $100.00 Price Target at Piper Sandler - MarketBeat
Piper Sandler Raises Arrowhead Pharma (ARWR) Price Target to $10 - GuruFocus
Piper Sandler raises Arrowhead Pharma stock price target to $100 on Redemplo launch - Investing.com UK
ARWR (Arrowhead Pharmaceuticals) 12-1 Month Momentum % : 84.44% (As of Dec. 17, 2025) - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 54,298 Shares - MarketBeat
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells 130,000 Shares of Stock - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching - ts2.tech
Arrowhead (ARWR) Experiences Notable Decline in Share Price - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 7.6%What's Next? - MarketBeat
Arrowhead (ARWR) Sees Significant Decline as Stock Drops Over 12% - GuruFocus
Hudson Bay Capital Management LP Purchases 46,870 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals Inc (ARWR) 財務データ
収益
当期純利益
現金流量
EPS
Arrowhead Pharmaceuticals Inc (ARWR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard | Chief Executive Officer |
Dec 29 '25 |
Option Exercise |
6.15 |
51,726 |
318,115 |
3,857,652 |
| Anzalone Christopher Richard | Chief Executive Officer |
Dec 29 '25 |
Sale |
69.13 |
51,726 |
3,575,575 |
3,805,926 |
| Ferrari Mauro | Director |
Dec 26 '25 |
Sale |
70.00 |
7,530 |
527,100 |
69,053 |
0.57%
大文字化:
|
ボリューム (24 時間):